These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 25467848)

  • 1. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
    Reilmann R; Anderson KE; Feigin A; Tabrizi SJ; Leavitt BR; Stout JC; Piccini P; Schubert R; Loupe P; Wickenberg A; Borowsky B; Rynkowski G; Volkinshtein R; Li T; Savola JM; Hayden M; Gordon MF;
    Lancet Neurol; 2024 Mar; 23(3):243-255. PubMed ID: 38280392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
    Sampson EL; Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005380. PubMed ID: 24563468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
    Sampson EL; Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
    Reilmann R; McGarry A; Grachev ID; Savola JM; Borowsky B; Eyal E; Gross N; Langbehn D; Schubert R; Wickenberg AT; Papapetropoulos S; Hayden M; Squitieri F; Kieburtz K; Landwehrmeyer GB; ;
    Lancet Neurol; 2019 Feb; 18(2):165-176. PubMed ID: 30563778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
    Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
    Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
    Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
    Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
    Faux NG; Ritchie CW; Gunn A; Rembach A; Tsatsanis A; Bedo J; Harrison J; Lannfelt L; Blennow K; Zetterberg H; Ingelsson M; Masters CL; Tanzi RE; Cummings JL; Herd CM; Bush AI
    J Alzheimers Dis; 2010; 20(2):509-16. PubMed ID: 20164561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of GABA
    Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
    Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
    Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
    Huntington Study Group HART Investigators
    Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
    Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
    Bigal ME; Edvinsson L; Rapoport AM; Lipton RB; Spierings EL; Diener HC; Burstein R; Loupe PS; Ma Y; Yang R; Silberstein SD
    Lancet Neurol; 2015 Nov; 14(11):1091-100. PubMed ID: 26432181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.
    Dodick DW; Goadsby PJ; Silberstein SD; Lipton RB; Olesen J; Ashina M; Wilks K; Kudrow D; Kroll R; Kohrman B; Bargar R; Hirman J; Smith J;
    Lancet Neurol; 2014 Nov; 13(11):1100-1107. PubMed ID: 25297013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.